Litigation Details for Sumitomo Dainippon Pharma Co., Ltd. v. Amneal Pharmaceuticals, LLC (D. Del. 2018)

Sumitomo Dainippon Pharma Co., Ltd. v. Amneal Pharmaceuticals, LLC (D. Del. 2018)

Docket		Date Filed	2018-02-13
Court	District Court, D. Delaware	Date Terminated	2018-05-01
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,729,085; 8,883,794; 9,259,423; 9,555,027; 9,815,827; 9,827,242
Attorneys	Karen Jacobs
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Sumitomo Dainippon Pharma Co., Ltd. v. Amneal Pharmaceuticals, LLC (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-02-13				External link to document
2018-02-12	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,815,827 B2. (nmfn) (Entered…February 2018 1 May 2018 1:18-cv-00256 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-02-12	7		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,815,827 B2. (Attachments: #…February 2018 1 May 2018 1:18-cv-00256 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Sumitomo Dainippon Pharma Co., Ltd. v. Amneal Pharmaceuticals, LLC (D. Del. 2018)

Last updated: July 5, 2026

Sumitomo Dainippon Pharma v. Amneal (1:18-cv-00256): Litigation Summary, Patent Scope, Timeline, and Generic Entry Risk

Executive summary: In Sumitomo Dainippon Pharma Co., Ltd. v. Amneal Pharmaceuticals, LLC, No. 1:18-cv-00256, the plaintiff (Sumitomo Dainippon Pharma) asserted US patent infringement against Amneal over an ANDA-style generic challenge. The dispute centers on whether Amneal’s proposed product infringes one or more asserted Orange Book-listed patents and whether any asserted patents are invalid and/or not infringed. The case’s outcome, including any stipulated settlement and effective entry date triggered by FDA regulatory actions, is the key driver of exclusivity and downstream generic launch timing.

What patents were asserted in Sumitomo Dainippon Pharma v. Amneal (1:18-cv-00256)?

Direct infringement claims and asserted patent IDs. The litigation record in this matter is tied to an Orange Book patent list for a specific Sumitomo Dainippon brand and Amneal ANDA. The infringement analysis in these cases typically maps to: (1) Orange Book patents listed for the reference listed drug (RLD), (2) Amneal’s Paragraph IV certifications, and (3) specific claims related to active ingredient use, formulations, or manufacturing.

Claim-scope drivers commonly litigated in Sumitomo Dainippon generics cases

• Method-of-use claims: therapeutic dosing, patient selection, or administration regimen.
• Formulation claims: release profile, excipients, particle size, stability, or dosage form.
• Process/manufacturing claims: steps and parameters enabling the same release or bioavailability.
• Bioequivalence design constraints: whether the ANDA design “meets” claim limitations when construed.

What this means for enforcement strategy

• If asserted claims are formulation and the ANDA relies on a different formulation approach, infringement risk can drop quickly at claim construction.
• If asserted claims are method-of-use, design-around is harder because generic dosing must still match the RLD label.

Result: Without the complaint’s asserted patent numbers and the court’s claim construction order (or final judgment docket entry), a complete patent-by-patent infringement/invalidity analysis cannot be produced.

What was the litigation timeline for 1:18-cv-00256 (filing, motions, and resolution)?

High-probability procedural milestones in ANDA patent cases

• Complaint filed after the ANDA submission and FDA acceptance.
• Early motion practice: motions to dismiss, claim construction scheduling, and discovery scope.
• Markman/claim construction rulings defining “infringement” and “invalidity” boundaries.
• Summary judgment or trial on infringement/invalidity (depending on posture).
• Final disposition: judgment, dismissal, or stipulated settlement that governs generic launch.

Key business relevance

• The date of any settlement agreement, if entered, often sets a “walk-away” or agreed-for-entry date.
• If the case resolved via consent judgment, the entry date can be tied to FDA approval plus any trigger date (often linked to patent expiration or a “carve-out”).
• If litigated through merits, the court’s construction and validity findings become reusable in future Orange Book and design-around disputes.

Result: A specific filing-to-resolution timeline cannot be stated from the information provided.

How did Amneal challenge infringement and validity in 1:18-cv-00256?

Common invalidity and non-infringement defenses

• Non-infringement: ANDA product does not meet claim limitations under proper claim construction.
• Invalidity: anticipation or obviousness based on prior art references.
• Written description/enablement: asserted claims not supported by the specification.
• Indefiniteness: claim language fails to provide objective boundaries.
• Prosecution history estoppel / disclaimer: narrowing effects from claim amendments and arguments.

What matters for “Paragraph IV” ANDA posture

• The court’s claim construction drives the infringement analysis.
• Obviousness and anticipation often turn on technical disclosures about release kinetics, dosage formulation, and pharmacokinetic equivalence.

Result: The specific defense theories and the court’s rulings on each cannot be summarized accurately without docket orders or the opinion/judgment.

What did the court decide in Sumitomo Dainippon Pharma v. Amneal (1:18-cv-00256)?

Decision categories

1. Infringement found, patents upheld: generic entry blocked until patent expiration.
2. Infringement found, patents invalidated: earlier generic entry possible.
3. No infringement: generic entry can proceed subject to any remaining patents.
4. Settlement/consent judgment: entry date set by agreement, with reduced uncertainty.

Post-judgment consequences

• If the court invalidates key claims, later generics can file sooner and with reduced litigation risk.
• If the court narrows claims via construction, design-around options may expand.

Result: A case outcome summary (who won on which patents, and whether any patents were held invalid or not infringed) is not computable from the provided prompt.

What is the Orange Book status tied to this lawsuit and how many patents were implicated?

Orange Book linkage mechanics

• Orange Book lists patents for the RLD, including drug substance, drug product, and method-of-use patents.
• In ANDA suits, the complaint typically identifies the specific Orange Book patents that are challenged via Paragraph IV certifications.
• The number of patents matters for both licensing and launch timing because only one blocking patent is often sufficient to delay approval or commercial launch.

How companies use Orange Book status

• Patent estate mapping to build launch strategies and contingency timelines.
• Freedom-to-operate (FTO) screening to determine whether additional design-around formulations are needed.

Result: The RLD name, listed patent family size, and Orange Book “listed” vs “expired” status cannot be stated without the underlying Orange Book listing tied to docket 1:18-cv-00256.

When does the asserted patent estate expire, and when does exclusivity end?

Two different timing clocks

• Patent expiration: statutory expiration date (including any term adjustment).
• Regulatory exclusivity: FDA periods such as 5-year NCE exclusivity or 3-year new clinical investigation exclusivity (for the RLD, not the ANDA itself).

ANDA settlement walk-outs

• Many settlements tie entry to either:
  • patent expiration, or
  • an earlier agreed date in exchange for licensing or nonexclusive terms.

Result: Specific expiration and exclusivity dates cannot be provided without the asserted patent numbers and their grant/expiration data.

What Paragraph IV effects did the case have on Amneal’s potential generic entry?

Practical impact

• During active litigation tied to Paragraph IV, FDA approval timing and marketing launch are constrained by statutory stay and any court outcomes/settlements.
• If there is a settlement, the effective launch date is often set even if an appeal or post-judgment motions occur.

Commercial exposure

• The “entry-risk” for other generics depends on:
  • how many patents were in the case,
  • which patents survived, and
  • whether the court made validity rulings that can be used in other cases.

Result: Launch timing and market-entry constraints are not derivable without the judgment or settlement entry terms.

What settlement agreements (if any) governed entry dates in 1:18-cv-00256?

Settlement fingerprints in ANDA cases

• Joint stipulation of dismissal (with prejudice) after settlement.
• Consent judgment or modified injunction.
• “Final” dismissal with express language about non-infringement or validity not being adjudicated.

Why settlement terms matter

• Settlement often includes:
  • an entry trigger date,
  • a covenant-not-to-sue period for certain products,
  • potential cross-licenses, and
  • restrictions on product design or labeling.

Result: Settlement terms cannot be summarized without the docket’s settlement documents.

How does this case compare with other Sumitomo Dainippon vs generic litigations involving Amneal or similar defendants?

Comparison dimensions

• Number and type of patents asserted (formulation vs method-of-use).
• Court venue and judge tendencies in claim construction.
• Frequency of settlements vs merits outcomes.
• Technical themes: bioavailability, release profile, or label-driven method-of-use.

Actionable takeaways

• If prior Sumitomo Dainippon cases show consistent claim construction outcomes, they can reduce uncertainty in subsequent ANDA disputes for similarly structured products.
• If method-of-use claims are repeatedly upheld, generic entry strategies may require label carve-outs or different dosing.

Result: Comparative analysis requires access to other specific case dockets and rulings.

What generic entry risks exist for competitors if Amneal prevailed or settled in 1:18-cv-00256?

Risk pathways

• If patents invalidated: competitors can cite invalidity logic, reducing cost of future challenges.
• If no infringement found: competitors can copy the design strategy that avoided claim limitations.
• If settlement sets an earlier date: market entry can reprice revenue risk for incumbents.

Portfolio-wide implications

• For Sumitomo Dainippon, one adverse case can weaken subsequent litigation leverage if the same claim language and same prior art appear.
• For generic manufacturers, one favorable outcome can justify additional filing activity around the same formulation or method-of-use concept.

Result: Case-specific competitor risk requires the actual disposition.

What FDA regulatory events were relevant to this lawsuit?

FDA events typically in the record

• ANDA filing acceptance by FDA.
• Patent certifications and required statements under 21 U.S.C. § 355(j)(2)(A)(vii).
• Parenteral/oral product-related CMC changes affecting product design around claim limitations.
• Any approval timing, tentative approval, or labeling constraints.

Why it matters

• If the ANDA was amended after the lawsuit (common in design-around strategies), the infringement analysis shifts to the “accused” version.
• Labeling and method-of-use scope determine whether method-of-use claims are implicated.

Result: Specific FDA milestones cannot be extracted from the prompt.

Key Takeaways

• The case is an ANDA-style patent infringement dispute between Sumitomo Dainippon Pharma Co., Ltd. and Amneal Pharmaceuticals, LLC under No. 1:18-cv-00256.
• A complete litigation summary requires the asserted US patent numbers, the court’s disposition (judgment vs settlement), and the Orange Book-linked RLD/patent list.
• Without those specifics, it is not possible to provide accurate, patent-by-patent infringement and invalidity analysis, settlement entry-date effects, or expiration-based launch timelines tied to the case.

FAQs

1. Does 1:18-cv-00256 involve method-of-use or formulation patents?
   Not determinable from the provided prompt.

2. Was the case resolved by a court decision or settlement?
   Not determinable from the provided prompt.

3. How do Paragraph IV certifications in this docket affect FDA approval and marketing?
   Depends on the dispute outcome and any settlement triggers; not determinable from the provided prompt.

4. Which Orange Book patents were at issue in Sumitomo Dainippon v. Amneal?
   Not determinable from the provided prompt.

5. What competitor launch risks follow the outcome of this litigation?
   Depends on whether patents were held infringed/valid and on any settlement entry date; not determinable from the provided prompt.

References

1. (No citable sources provided in the prompt content.)